Skip to main content

Advertisement

Erratum to: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?

Article metrics

The original article was published in BMC Medicine 2017 15:55

Erratum

After publication of the original article [1], it came to the publisher’s attention that the text contained several minor typos. Upon investigation, it transpired that there had been technical issues affecting the copyediting process before the article entered the production stage, resulting in the presence of minor errors, without influence on content, in the published version.

The original article has now been updated in order to rectify these errors, comprising of textual edits that do not affect the scientific content of the paper.

Reference

  1. 1.

    Remon J, Besse B, Soria JC. Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? BMC Med. 2017;15:55. doi:10.1186/s12916-017-0819-3.

Download references

Author information

Correspondence to Jean-Charles Soria.

Additional information

The online version of the original article can be found under doi:10.1186/s12916-017-0819-3.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Remon, J., Besse, B. & Soria, J. Erratum to: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?. BMC Med 15, 82 (2017) doi:10.1186/s12916-017-0857-x

Download citation